Novartis to resume enrollment in ongoing study of branaplam in type 1 SMA

Effective immediately, following the respective Health Authorities and Ethics Committee approvals, Novartis will be resuming enrollment in the ongoing study in type 1 SMA (CLMI070X2201) at their existing sites in Belgium, Germany, Denmark and Italy.

Please click here to read the full letter.